Black Titan (BTTC) and Its Competitors Critical Review

Black Titan (NASDAQ:BTTC) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its rivals? We will compare Black Titan to related businesses based on the strength of its valuation, institutional ownership, analyst recommendations, earnings, profitability, risk and dividends.

Institutional & Insider Ownership

56.4% of shares of all “Services – Computer Programming And Data Processing” companies are owned by institutional investors. 0.7% of Black Titan shares are owned by company insiders. Comparatively, 16.4% of shares of all “Services – Computer Programming And Data Processing” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Black Titan has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.54, indicating that their average stock price is 46% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Black Titan and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	100	204	222	14	2.28

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 124.32%. Given Black Titan’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Black Titan has less favorable growth aspects than its rivals.

Profitability

This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-63.65%	-919.53%	-68.53%

Earnings & Valuation

This table compares Black Titan and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.52
Black Titan Competitors	$257.01 million	-$80.63 million	-9.90

Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Black Titan rivals beat Black Titan on 8 of the 13 factors compared.

Black Titan Company Profile

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.